Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

被引:88
作者
Lee, Ju-Hee
Park, Jung-Hyun
Jung, Yeonjoo
Kim, Jee-Hyun
Jong, Hyun-Soon
Kim, Tae-You
Bang, Yung-Jue
机构
[1] Seoul Natl Univ, Coll Med, Div Hematol Med Oncol, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Tumor Biol, Seoul 110744, South Korea
[3] Seoul Natl Univ, Coll Med, Natl Res Lab Canc Epigenet, Inst Canc Res, Seoul 110744, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea
关键词
D O I
10.1158/1535-7163.MCT-06-0419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thymidylate synthase (TS) overexpression is a key determinant of 5-fluorouracil (5-FU) resistance in human cancer cells. TS is also acutely up-regulated with 5-FU treatment, and, thus, novel strategies targeting TS downregulation seem to be promising in terms of modulating 5-FU resistance. Here, we report that histone deacetylase inhibitors can reverse 5-FU resistance by down-regulating TS. By using cDNA microarrays and validation experiments, we found that trichostatin A reduced the expression of both TS mRNA and TS protein. Cotreatment with trichostatin A and cycloheximide restored TS mRNA expression, suggesting that TS mRNA is repressed through new protein synthesis. On the other hand, TS protein expression was significantly reduced by lower doses of trichostatin A (50 nmol/L). Mechanistically, TS protein was found to interact with heat shock protein (Hsp) complex, and trichostatin A treatment induced chaperonic Hsp90 acetylation and subsequently enhanced Hsp70 binding to TS, which led to the proteasomal degradation of TS protein. Of note, combined treatment with low-dose trichostatin A and 5-FU enhanced 5-FU mediated cytotoxicity in 5-FU-resistant cancer cells in accordance with TS protein down-regulation. We conclude that a combinatorial approach using histone deacetylase inhibitors may be useful at overcoming 5-FU resistance.
引用
收藏
页码:3085 / 3095
页数:11
相关论文
共 50 条
[1]  
ALLEY MC, 1988, CANCER RES, V48, P589
[2]   Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy [J].
Aschele, C ;
Debernardis, D ;
Casazza, S ;
Antonelli, G ;
Tunesi, G ;
Baldo, C ;
Lionetto, R ;
Maley, F ;
Sobrero, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1760-1770
[3]   A "combination oligonucleotide'' antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance [J].
Berg, RW ;
Ferguson, PJ ;
Vincent, MD ;
Koropatnick, DJ .
CANCER GENE THERAPY, 2003, 10 (04) :278-286
[4]   Epigenomics and epigenetic therapy of cancer [J].
Brown, R ;
Strathdee, G .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S43-S48
[5]   A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia [J].
Byrd, JC ;
Marcucci, G ;
Parthun, MR ;
Xiao, JJ ;
Klisovic, RB ;
Moran, M ;
Lin, TS ;
Liu, SJ ;
Sklenar, AR ;
Davis, ME ;
Lucas, DM ;
Fischer, B ;
Shank, R ;
Tejaswi, SL ;
Binkley, P ;
Wright, J ;
Chan, KK ;
Grever, MR .
BLOOD, 2005, 105 (03) :959-967
[6]   THE CATALYTIC MECHANISM AND STRUCTURE OF THYMIDYLATE SYNTHASE [J].
CARRERAS, CW ;
SANTI, DV .
ANNUAL REVIEW OF BIOCHEMISTRY, 1995, 64 :721-762
[7]   Thymidylate synthase inhibitors as anticancer agents: from bench to bedside [J].
Chu, E ;
Callender, MA ;
Farrell, MP ;
Schmitz, JC .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (Suppl 1) :S80-S89
[8]   Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis [J].
Cohen, HY ;
Lavu, S ;
Bitterman, KJ ;
Hekking, B ;
Imahiyerobo, TA ;
Miller, C ;
Frye, R ;
Ploegh, H ;
Kessler, BM ;
Sinclair, DA .
MOLECULAR CELL, 2004, 13 (05) :627-638
[9]   THYMIDYLATE SYNTHASE GENE AMPLIFICATION IN HUMAN COLON-CANCER CELL-LINES RESISTANT TO 5-FLUOROURACIL [J].
COPUR, S ;
AIBA, K ;
DRAKE, JC ;
ALLEGRA, CJ ;
CHU, E .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (10) :1419-1426
[10]  
Jackman AL, 1997, CLIN CANCER RES, V3, P911